Poor
Poor Alignment
Patient Risk:
Low
Summary
The AI-generated claims partially align with the label on grapefruit-atorvastatin interactions (e.g., increased atorvastatin levels and general drug interaction warnings) but include multiple unsupported or contradicted statements (e.g., specific mechanism details, kidney risk, dramatic life-threatening risk, and certain consumer guidance). Overall alignment is limited with substantial omissions and contradictions relative to the label.
Category Scores
Accurate Statements
Lipitor, also known as atorvastatin, is a statin medication used to treat high cholesterol levels by reducing the amount of low-density lipoprotein (LDL) cholesterol in the blood.
1 INDICATIONS AND USAGE
Grapefruit juice has been shown to increase the levels of atorvastatin in the bloodstream.
7.2 Grapefruit Juice
Increased levels of atorvastatin can lead to an increased risk of side effects.
7.2 Grapefruit Juice
Increased risk of side effects includes muscle weakness.
6 ADVERSE REACTIONS, 7.2 Grapefruit Juice
Increased risk of liver damage.
6 ADVERSE REACTIONS
Grapefruit juice can interact with other medications.
7 DRUG INTERACTIONS, 7.2 Grapefruit Juice
The short answer is no; it is not recommended to mix grapefruit juice with Lipitor.
7 DRUG INTERACTIONS, 7.2 Grapefruit Juice, 17 PATIENT COUNSELING INFORMATION
Consult with your doctor or pharmacist to discuss the risks and benefits of grapefruit with Lipitor.
17 PATIENT COUNSELING INFORMATION
It is generally recommended to avoid eating grapefruit or drinking grapefruit juice if you are taking Lipitor.
7 DRUG INTERACTIONS, 7.2 Grapefruit Juice, 17 PATIENT COUNSELING INFORMATION
Unsupported Statements
Grapefruit juice contains compounds called furanocoumarins.
Not supported by label content provided; label indicates CYP3A4 inhibition but does not specify furanocoumarins.
Furanocoumarins inhibit the metabolism of certain medications, including statins.
Not explicitly stated in the provided label sections.
Increased risk of kidney problems.
Not supported by the specific label content provided for adverse kidney risks.
These interactions include blood thinners, diabetes medications, and blood pressure medications.
Not specified in label interactions sections; not listed as examples in 7.1/7.2.
Eating grapefruit segments avoids the risk of interacting with Lipitor.
Label guidance generally cautions avoidance; the claim asserts an avoidance strategy not supported by label text.
Choosing a different statin may be an alternative if grapefruit interactions are a concern.
Not explicit in the provided label sections.
You may want to consider switching to a different statin medication.
Not explicit in the provided label sections.
Grapefruit juice interaction with Lipitor risks are not yet fully understood.
Label indicates clear interaction risk; claim contradicts the label.
Grapefruit juice can lead to potentially life-threatening interactions with Lipitor.
Label does not characterize interactions as life-threatening; this overstates risk.
Alternatives to grapefruit juice include pomegranate juice or green tea, but you should consult your doctor or pharmacist before taking any new supplements or medications.
Not specified in the label; constitutes non-label supplement guidance.
Contradictions
Low
AI Statement
Grapefruit juice interaction with Lipitor risks are not yet fully understood.
Label Reference
7.2 Grapefruit Juice
Low
AI Statement
Grapefruit juice can lead to potentially life-threatening interactions with Lipitor.
Label Reference
7.2 Grapefruit Juice
Important Omissions
No explicit mention of furanocoumarins as the active components in Grapefruit Juice causing CYP3A4 inhibition in the label summary.
Importance:
Moderate
Kidney-related adverse events are not clearly described as a primary risk in the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The label documents increased atorvastatin exposure with grapefruit juice and associated risks (myopathy, liver enzyme abnormalities); however, the overall risk to the general population is typically low unless other risk factors exist.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poor Alignment
Primary Issue
Multiple claims are unsupported or contradicted by the FDA-approved label; several statements mischaracterize the mechanism and risk (e.g., furanocoumarin specifics, kidney risk, life-threatening risk).
Suggested Improvement
Align all grapefruit/Lipitor interaction statements with label sections (7.2 Grapefruit Juice, 7 Drug Interactions, 5.1, 6) and avoid asserting mechanisms or risks not explicit in the label; limit guidance to what appears in the labeling, including explicit warnings to avoid grapefruit and counseling language.